Hoth Therapeutics, Inc. (HOTH)
After hours:
| Previous close | 1.0700 |
| Open | 1.0100 |
| Bid | 0.9545 x 200 |
| Ask | 1.0600 x 100 |
| Day's range | 0.9501 - 1.0300 |
| 52-week range | 0.5800 - 1.7900 |
| Volume | |
| Avg. volume | 3,805,006 |
| Market cap | 6.973M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5500 |
| Earnings date | 11 Nov 2024 - 15 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
PR NewswireHoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi
ZacksHoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
- PR Newswire
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
